Poor adherence with ACE inhibitors is a risk factor of CVA with oral hypoglycemic agents in diabetic patients

Poor adherence with medicine declines the clinical outcome of pharmacotherapy. it may carry serious sequelae especially in case of antihypertensive drugs like cerebrovascular accident (cva). this study has been planned to find the association of poor adherence with anti-hypertensive with cva in diabetic and non- diabetic patients. one hundred cva patients who were admitted through emergency in abbasi shaheed hospital,a tertiary care hospital in karachi,were recruited from jun 2013 till dec 2013. the criteria of inclusion was,diagnosed case of cva,with primary hypertension,availability of patient's therapeutic record,consent of the patient or legal successor/heir. the criteria of exclusion was,secondary hypertension,newly diagnosed primary hypertensive patients and complete adherence with medication. morisky medication adherence scale was applied. therapeutic record was accessed. the mean age was 62.15 years with 3:1 male to female ratio. adherence to medicine was graded <6. patients with hypertension were 41 and with diabetes and hypertension were 59. majority of patients were on monotherapy as compared to polytherapy (62% versus 38%).the mode of therapy was significantly different (p<0.05) in the two groups. ace inhibitors,calcium channel blockers,beta blockers and other agents were used by 45.16%,35.48%,16.12% and 03.24% patients respectively. the aforementioned drugs were used by 57.14%,33.33% and 09.52% respectively in 21 patients who were on antihypertensive and oral hypoglycemic agents. a statistical significant difference (p<0.05) was seen in the case of ace inhibitors. similarly they were used by 42.10%,39.47% and 18.42% in 38 patients respectively,who were on antihypertensive and insulin. no statistical significant difference (p>0.05) was seen in any combination (p>0.05). thus it is concluded that poor adherence with ace inhibitors may be a risk factor of cva in diabetic patients using oral hypoglycemic agents.